Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism
Clinica chimica acta; international journal of clinical chemistry, 2016.
CYP2C9Deep venous thrombosisPulmonary embolismRivaroxabanVKORC1
Pulmonary embolism (PE) is a life-threatening manifestation of venous thromboembolism. Rivaroxaban is an oral anticoagulant, which directly inhibits Factor Xa. The objective of the current study was, in comparison to the standard-therapy method, to investigate the potential of rivaroxaban to improve the treatment of patients with PE, and ...More
Full Text (Upload PDF)